TCBI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Texas Capital Bancshares Inc (TCBI) is not a strong buy for a beginner, long-term investor at this moment. While the company has shown strong financial performance in Q4 2025 and has received positive price target revisions from analysts, the stock is currently trading in a neutral technical zone with no clear upward momentum. Additionally, recent news raises concerns about financial stability, and there is no strong signal from Intellectia Proprietary Trading Signals to support an immediate buy decision. Given the investor's preference for long-term investments, it is better to wait for a more favorable entry point or stronger positive catalysts.
The technical indicators are mixed. The MACD is positive and expanding, suggesting bullish momentum. The RSI is neutral at 63.169, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its pivot point (93.051) with resistance at 95.416 and support at 90.687, indicating limited short-term upside potential.
Hedge funds are significantly increasing their holdings, with a 640.85% increase in buying over the last quarter.
Strong Q4 2025 financial performance with revenue up 15.34% YoY, net income up 44.42% YoY, and EPS up 52.52% YoY.
Analysts have raised price targets, with several firms highlighting strong earnings and operational improvements.
Recent news highlights concerns about financial stability despite positive stock performance.
The stock is not included in Motley Fool's top investment list, suggesting caution.
Insider trading activity is neutral, with no significant buying trends.
The stock has a 60% chance to decline by -1.83% in the next day and -0.39% in the next week, based on similar candlestick patterns.
In Q4 2025, Texas Capital Bancshares delivered strong results: Revenue increased by 15.34% YoY to $317.47M, net income rose by 44.42% YoY to $96.35M, and EPS grew by 52.52% YoY to $2.12. These results indicate robust growth and effective cost management.
Analysts have generally raised price targets, with the highest being $114 and the lowest at $88. Outperform and Overweight ratings dominate, but there are also Neutral and Sell ratings, reflecting a mixed sentiment. Analysts highlight strong earnings, expense control, and operational improvements but caution about slower balance sheet growth in 2026.
